PowerByProxi and Minimonos in top 10 for BNZ Virgin Business Challenge

The BNZ Virgin Business Challenge awards dinner was held last Thursday night. 260 companies entered this challenge with 10 going through to the final judging phase on Wednesday and Thursday.  The finalists were competing for a $100k cash prize, international travel and time with one of the world’s leading entrepreneurs Richard Branson. MOVAC investee companies PowerByProxi (Fund 2 and 3) and Minimonos (Fund 2) made the short list.

FaceMe, an online video conferencing solution for businesses took out the award, but all 10 companies were outstanding. The NZ innovation sector is in great shape!

The interviews conducted with Greg Cross from PowerByProxi and Milessa Clark-Reynolds from MiniMonos can be seen below.  The full list of finalists can be found on the BNZ website.

 

How Steve Jobs influenced my life

Steve jobs with Apple IIThe world has lost one of this generations greatest influencers.  There’s not many who can lay claim to have profoundly shaped the world that we live in, but Steve Jobs can.  I did not know the man but my career has been shaped by the products he created and my children grow up in a world where iPhones, iPads, Macs and the AppleTV are all second nature.

My experience goes back to my early childhood, my Dad was Deputy Principal at Napier Boys’ High School where he set up the School’s first computer lab with AppleII computers.  He’d bring one of them home in the weekend and it was through this, at the age of about 10 that I started to be drawn to computing as a career.  Firstly playing games like…Pong, Brick out, Lemonade Stand…and then programming from about the age of 12 – started by copying out assembler code from computer mags for games like Frogger, Space Invaders (both of which I’ve just reinstalled on my iPad).

Steve Jobs had an undeniable passion for what he did.  Passion, to make a difference.  Such passion is well established as one of the key ingredients in the world’s most successful businesses.  It’s something we’ve come to actively look for in the people we back…have they got a little bit of Steve Jobs in them?

For the past 33 years, I have looked in the mirror every morning and asked myself: “If today were the last day of my life, would I want to do what I am about to do today?” And whenever the answer has been “No” for too many days in a row, I know I need to change something.

Steve Jobs

My early exposure to Apple, the influence of the undeniably approachable Apple technology and Steve’s entrepreneurial example have shaped what I do today.

Thanks Steve, go in peace.

MeSynthes wins Wellington Supreme Gold award

Mesynthes LImited, backed by MOVAC, has received a significant acknowledgement by winning the Wellington Supreme Gold award last night. Founded in 2008 by Dr Brian Ward, Mesynthes has developed a unique tissue substitute, derived from the forestomach of sheep, that supports and encourages tissue growth. The product is used to promote wound healing and in plastic surgery.  Mesynthes received US Food and Drug Administration approval last year and expects to ship its first commercial product in the second half of 2011.  Read more here…Mesynthes supreme winner at Wellington Gold Awards.

Congratulations to Brian and the rest of team.

3rd Annual Angel Summit

The 3rd Angel Investor Summit was held in Nelson two weeks ago. The key themes for this years summit – apart from sampling the outstanding local cuisine – were:

  • Building global businesses from NZ; and
  • Exit – getting out of the business of being stuckholders

We had an excellent range of domestic and international speakers with representatives from China, India, Australia and the United States. The local crew in the form of Rod Drury (Xero) and Derek Handley (Hyperfactory) provided excellent insights into their globalisation and exit experiences; and Scott Gilmour (I have a dream) and Sam Morgan provided the evenings inspiration by sharing their experiences with philanthropy.

For me, the key takeaways from the conference were:

  • The upbeat feeling and camaraderie developing between Angel investors not just up and down the county but also with our international colleagues. There is a huge opportunity to build on this and leverage these deepening networks to help take New Zealand businesses to the next level on the global stage.
  • The tight collaboration occurring between Angel groups up and down New Zealand.  The level of cooperation is partly in response to the lack of venture funding in New Zealand, but enables us to more effectively leverage the small pockets of experience we have in NZ.
  • Our unique global position. I describe this as “we’re a village but on a global stage we’re highly respected and get country credibility”. Practically this means we have extraordinary access to global influencers and when we work closely with the NZ government on the international stage – stuff happens. In NZ we’re all only 2 or 3 degrees separated from the Prime Minister or the NZ Ambassador in the US or the NZ Ambassador in China…in what other country in the world could you build a global business with this level of access?
  • The gradual shift in the risk / return profile Angels are seeking.  Historically Angels, largely lead by thinking from the US, have been following a 30 times return, 1 in 10 investment profile.  Basically we’ve sought to build a portfolio of investments where one would “shoot the lights out”, a couple would “do OK” and we’d “lose on the rest”.  With the massive contracting occurring in Venture Capital world-wide Angels / Private investors are being required to invest deeper and longer.  The response we’re seeing to this is a shift to the centre – a focus on smaller returns but lower risk.  This thinking is being lead by Basil Peters and supported by his experience and research published in his book called Early Exits.  I encourage all of you to read this book.

Interestingly, I think that this conference is starting to get so good now that the international networking achieved at the NZ conference is just as powerful as what I managed to achieve in the US and Singapore conferences earlier in the year.  On a further note i’m aware of at least two deals that were struck between investors at the conference and the seeds sewn for a new angel group.

Arch Angel Award

We also announced this years recipient of the NZ Arch Angel award – Bill Payne. Oddly for this award Bill is an American, so what were doing given this award to Bill? Simply put Bill has been helping the development of the NZ Angel scene extensively over that last 3 or more years. His contribution culminated in this years extended stay where he had a dramatic impact on raising the profile of angel investment, assisting angels groups and providing one on one mentoring to a huge number of NZ entrepreneurs. Thanks to Bill and we look forward to seeing him out again next year.

MOVAC Team expanding

We’re starting to build some good momentum pulling together our next investment partnership. Creatively we’ve called this Fund 3 (thought of the name myself) and the plan is to focus on the early expansion end of the market – companies with some good proof behind them, needing up to $5 million to accelerate their entry into markets.  We hope to have this Fund up and running in the early part of the new year.

I’m really pleased to announce some excellent additions to our team for Fund 3:

Richard Palmer – Richard is joining us as a General Partner (technical term meaning that he will do real work) after spending the last four years with NZVIF where he lead the Seed Co-investment Fund. Richard brings additional insights into the NZ investment scene to the MOVAC team along with significant experience of operating Venture Funds internationally. We’re making good progress with Richard, since joining he’s lost the tie and last week even the ‘chinos’ were left at home.

James Graham – James is joining us as a Venture Partner (technical term for a very important person, with loads of experience, but won’t be overworked day-to-day). James is an Irwi (Irish Kiwi) who relocated to New Zealand many years ago after a distinguished international banking career. James is an active investor in early stage New Zealand companies and compliments us by bringing an exceptional international network along with his experience of founding an IP commercialisation business in the UK. While James remains loyal to Irish rugby, he’s really a closet All Black supporter.

Greg Cross – Greg is joining us as a Venture Partner and is the executive chair of one of our existing portfolio companies – PowerByProxi. Greg has been an active supporter of the New Zealand entrepreneurial sector for many years. He has just handed over the chair role for the NZTE Beach Heads programme after serving as the founding chair for six years and is the current chair of the IceHouse incubator in Auckland. Greg further extends our ability to tap into international networks to help accelerate the growth of the companies we invest in. Greg’s real passion is cycling, in his spare time he’s leading the charge to get a Kiwi team competing in the Tour de France by 2015.

I’m really excited that Richard, James and Greg have agreed to join us in the next chapter of MOVAC’s journey. They’re great compliments to our team and each incredibly able and passionate about working with and helping young NZ companies.

Movac partners with SCIF

After a long courting period I’m pleased to announce that we’ve entered a formal partnership with the New Zealand Venture Investment Fund (NZVIF) for their seed fund (seed co-investment fund / SCIF).

This partnership enables us to access up to an additional $500,000 in matching funds for early stage New Zealand companies that we’re backing, or could be backing in the future.

I have to admit that we were pretty skeptical of the SCIF programme when it first launched a number of years back. But we’ve been proven wrong and found the people at NZVIF to be incredibly professional, knowledgable and respectful in their approach to supporting the early stage investment market.

We now have seven companies in our current portfolio that are receiving a leg up from SCIF.

Press release below….

NZVIF partners with Movac to invest in young companies

The New Zealand Venture Investment Fund and prominent Wellington angel investment group Movac are forming an investment partnership which will see NZVIF investing up to $4 million into new companies alongside investments made by Movac.

Movac Director Phil McCaw said the partnership with NZVIF’s Seed Co-Investment Fund will increase the capital available to develop a number of highly promising young companies.

“New Zealand produces great ideas and really promising companies. What we, as a country, lack to some extent is capital. What has been pleasing, from both entrepreneurs’ and the industry’s perspective, is the growing level of angel investment in recent years which is assisting innovative young companies to grow.

“We have already invested into a number of companies alongside NZVIF, via existing co-investment partnerships NZVIF has with other angel groups. Establishing this investment partnership will increase the pool of growth capital available to the promising companies which Movac invests into.”

This is the twelfth partnership NZVIF has entered into through the Seed Co-Investment Fund and the first in Wellington. To date, NZVIF and its angel partners have co-invested over $44 million into 40 companies.

When Movac invests into a new company which fits NZVIF’s criteria, NZVIF will match that one-to-one through its Seed Co-Investment Fund.

NZVIF chief executive Franceska Banga said that angel investors are the mainstay of investment for high growth start-ups in New Zealand and the best source of both advice and capital for entrepreneurs starting down the path of building a global company.

“NZVIF is keen to encourage more angel investors to assist in building the pipeline of young innovative start-ups.

“The more active and strong angel groups we have, like Movac, the greater the pool of capital to build the pipeline of young businesses. Angel investing is becoming an important asset class in terms of commercialising New Zealand innovations.”

Internet Industry Awards 2010 – open for applicatons

NEWS RELEASE

Applications are now open for the 2010 New Zealand Internet Industry Awards

Following on from the inaugural Internet Industry Awards launched in 2009 The Liz Dengate Thrush Foundation is pleased to announce that applications for the 2010 New Zealand Internet Industry Awards are now open.

These Awards are New Zealand’s premier awards focused on the Internet as an enabling platform for business, education and society enhancing organisations.

By honouring and celebrating those companies who have leveraged the transformational deliverables of the Internet the Awards seek to recognise excellence and showcase best practice to the wider community.

In addition to three company Awards launched last year The Liz Dengate Thrush Foundation has added a fourth company Award  focusing on recognising a company which has utilised the Internet to create a borderless platform for doing business. The fifth category recognises an individual - someone who is an Internet Innovator or Entrepreneur . A rare type of person who has put both capital and reputation on the line and has developed an Internet initiative that has successfully contributed to New Zealand’s wealth.

More about this year’s Categories:

Five distinct Categories have been developed to reflect the wide ranging impact of the Internet on New Zealand society . This impact can be realised at an individual, group, company or market (New Zealand or offshore) level. Applications must be from New Zealand based companies or individuals. 

Positive Societal Impact - Development of the application, product or services provided on the Internet likely to have the most beneficial impact on New Zealand society.

Best Education Product or Service on the Internet - The application, product or services provided on the Internet that is likely to have the greatest impact on learning and/or teaching in New Zealand.

Best Business Application – For those that transform their methods of doing business, or change our way of doing business with them.

Best Global Application on the Internet – For those companies that have used the fact the Internet promotes a borderless platform to do business on a global basis. This could be an internal application - the linking of country offices or an external application to reach target audiences within other geographies.

Internet Innovator or Entrepreneur – Recognition for that rare breed who put capital and reputation on the line and successfully contribute to New Zealand’s wealth.

Award winners will be announced at a black-tie dinner at Parliament’s Banquet Hall on Wednesday 28 July 2010.

To reserve your seats please contact Margie Sharpe – 021 767 530 or email Margie at margie.sharpe@xtra.co.nz

For more information visit www.internetindustryawards.co.nz or phone:

Catherine Gardiner
New Zealand Internet Industry Awards
09 361 2112
0274 899 768
catherine.gardiner@prescientmc.co.nz

Mesynthes Obtains U.S. FDA 510(k) Clearance for Endoform Dermal Template™

Novel Biomaterial for Wound Healing and Regenerative Medicine

WELLINGTON, NZ (February 2, 2010): Mesynthes, a privately held regenerative medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Endoform Dermal TemplateTM. Endoform, a proprietary extracellular matrix biomaterial, provides a unique biologic template for tissue regeneration.

“FDA marketing clearance for Endoform Dermal TemplateTM paves the way for commercial launch into the U.S. dermal market and establishes our EndoformTM platform as a new medical biomaterial for tissue repair and reconstruction,” said Dr. Brian Ward, Chief Executive Officer.

Mesynthes’s EndoformTM technology utilizes a proprietary extracellular matrix biomaterial containing a complex mixture of important biological molecules, including structural and adhesive proteins, such as collagens, elastin, fibronectin and laminin, and glycosaminoglycans.

“In tissue regeneration, it is now well recognized that a diverse mix of extracellular matrix components is important for orchestrating a regenerative response. These components provide important structure, signals, and substrates to cells within the healing tissue,” said Dr. Ward. “Once applied to the wound bed, the Endoform Dermal TemplateTM provides a uniquely supportive environment to guide the growth of cells and new tissue. Over time, EndoformTM is completely replaced by the patient’s own tissue. Clinically, the impact of applying extracellular matrix within a chronic wound is to restart the stalled healing process and stimulate new tissue growth in the wound bed. In acute wounds, extracellular matrix replaces lost dermis, advancing the wound healing process and reducing contracture.”

Chronic wounds are difficult to heal, require ongoing care, and risk complications that can lead to amputation. In the United States, the treatment costs of chronic and complex wounds have been estimated to be $20 billion per year, which creates a significant burden on the healthcare system.

Endoform Dermal TemplateTM provides a new tool to address this important issue. About the Endoform Dermal TemplateTM
Endoform Dermal TemplateTM is presented as a sterile dry sheet in a peel pouch and is strong and easy to handle in a dry or wet state. It is applied directly to the wound bed, then rehydrated, covered with a non-adherent dressing, and secured in place. EndoformTM is quick and easy to apply, available off-the shelf, and doesn’t require special storage.

Endoform Dermal TemplateTM is intended for the management of a wide variety of wounds including:

  • partial and full-thickness wounds
  • pressure ulcers
  • venous ulcers
  • diabetic ulcers
  • chronic vascular ulcers
  • tunnelled/undermined wounds
  • surgical wounds (donor sites/grafts, post-Moh’s surgery, post-laser surgery, podiatric, wound
  • dehiscence)
  • trauma wounds (abrasions, lacerations, second-degree burns, and skin tears)
  • draining wounds

Endoform’s unique features include its innate biology, strength, size, usability, and versatility. Also, Mesynthes’ proprietary processing and ovine (sheep)-derived biomaterial combine to add a new level of xeno-biological safety and cultural acceptability.

Mesynthes is developing a suite of medical devices for applications in regenerative medicine including products for wound care and soft tissue reconstruction based on the EndoformTM platform.

About Mesynthes
Mesynthes Ltd. is a privately held regenerative medicine company that has developed EndoformTM, a novel extracellular matrix platform for soft tissue repair and reconstruction. For more information on Mesynthes and its technology and products, please visit our web site at http://www.mesynthes.com.

Contacts:
Brian Ward
Mesynthes Chief Executive Officer
Ph: +64 21 727646
Email: brian.ward@mesynthes.com

Joan Kureczka
Kureczka/Martin Associates
Ph: +1 (415) 821 2413
Email: Jkureczka@comcast.net

AngelLink welcomes Life Science Angels Network

Hamilton, New Zealand – 6 November, 2009 – AngelLink, a national angel investment network backing New Zealand high growth technology ventures, with an emphasis on life sciences, engineering and ICT, welcomes the inclusion of the Life Science Angels Network into its structure.  The move is designed to create greater scale and focus in the life sciences angel investment space.

AngelLink’s members include some of the country’s leading biotechnology and high technology investors including Movac, K1W1 and Sparkbox.  AngelLink has also partnered with the NZ Venture Investment Fund (NZVIF) through its Seed Co-Investment Fund.

AngelLink Chairman Chris de Boer says, “Our national network of angel investors and international partnerships provide excellent leverage for high-growth potential start-up companies that are seeking to develop unproven markets or technologies.  Life sciences are a key part of AngelLink’s focus. The inclusion of the Life Science Angels Network helps AngelLink achieve greater scale and expertise in this area.  As a result we’ll see more investment activity in the life sciences space which will benefit the network and the sector in New Zealand.”

The Life Science Angels Network was created by a collaboration between NZBIO, ICE Angels and Auckland Plus to validate the concept of creating a virtual network of angel investors who are interested in investing in life science technology deals.

Andy Hamilton, Director, ICE Angels says, “When it comes to early stage funding there is a case for some sectors, such as life sciences, to have specialisation.  The ongoing viability of the sector depends on its ability to raise funds from a variety of sources and to complete value-creating deals. This access to funding is consistently one of the key constraints identified across the bioeconomy in New Zealand yet, based on international experiences angel investment has the ability to be a key part of the funding solution.”

“Having validated the need for The Life Science Angels Network we readily came to the conclusion that the natural home for the network was actually AngelLink as they already have in place a number of critical partnerships for deal flow in the life sciences space.  As a small country we need to take every opportunity to achieve scale.”

The merger will include all research, contacts and emerging international partnerships, including the Australian Life Science Angel Network, Life Science Angels Inc (USA) and Bansea, Singapore.

NZBIO, the national bioscience industry group, has applauded the transfer to AngelLink.

Chief Executive Bronwyn Dilley says, “AngelLink’s strong focus on life sciences and nationwide coverage will be further strengthened by the inclusion of the Life Science Angels Network.  Angel Investment is an important part of the investment landscape and a strong, focused approach is vital to the success of a mature New Zealand life science industry. It’s great to see AngelLink continue to gain momentum, as the result will be more early stage life science projects are spun out of the lab into the market with benefits to all.”

AngelLink, which was initiated by WaikatoLink, the commercial arm of the University of Waikato, connects investees to the full continuum of funding through its lifecycle from science to market spanning proof of concept, angel investment, early stage venture capital, expansion stage venture capital, and public markets.

AngelLink was launched at a function at NZX in August.  The Minister for Research, Science and Technology, Wayne Mapp was the guest of honour.

At the launch, WaikatoLink Chief Executive Mark Stuart said, “At an industry level there is a real need to make some improvements to generate more economic benefit from life sciences and technology research.  We need to start with the end in mind and bring the market in from the start. We need to encourage a co-ordinated approach and funding models that encourage collaboration rather than competition.  AngelLink represents a step change in early stage company investment by formalising visibility to upcoming investment opportunities to all of the partners across the investment continuum”.

Dr Mapp said, “The highest priority for the New Zealand Government is growth. Future opportunities will depend on innovation and entrepreneurship and much of this comes from fundamental science. AngelLink will connect research and investors with the intent of getting science to the marketplace. Our future prosperity depends on getting this right.”

The first Australasian Life Science Angels Network Meeting today in Queenstown, part of the annual summit organised by the Angel Association of New Zealand, is the setting for the first meeting between AngelLink, the Australian Life Science Angel Network and Bansea, Singapore.

For more on AngelLink see http://www.angellink.co.nz

Tindall becomes NZ’s first ‘Arch Angel’

Sir Stephen Tindall has been appointed the first ever New Zealand Arch Angel at the Angel Association of New Zealand’s second Angel Summit in Queenstown on Friday.

Angel Association Chair Andrew Hamilton said the award of Arch Angel honours Sir Stephen’s extraordinary contribution to the angel investing industry.

“Sir Stephen Tindall has invested over $150 million in seed and venture capital companies – both directly and as a fund-of-funds. He and his family have invested in over 100 New Zealand companies.

“His passion is to assist young entrepreneurs and he has invested in a variety of sectors including biotech, clean tech, IT and design led companies. He wants to see New Zealand develop as a leader in the ‘knowledge economy’, and to help create a culture of making New Zealand ‘cash flow positive’ in international goods and services trade.

“Sir Stephen’s wider contribution to New Zealand has been exceptional , including his charity work, founding Kea – the expat organisation that now has over 25,000 members worldwide, focusing on climate change, or actively investing into emerging Kiwi companies that are now taking on world markets. His contribution is quite extraordinary in a world-setting and we are extremely grateful to Stephen for his continued support and investment.”

Follow

Get every new post delivered to your Inbox.

Join 109 other followers